ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

AARON MORITA M.D., F.A.C.P.

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,928Medicare Part D Prescriptions Filled, Including Refills

Rank: 24 out of 315

$619K Total Retail Price of All Prescriptions

Rank: 42 out of 315

398 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Hawaii
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 398 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

13% of this provider’s 398 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 10,379 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Hawaii
PRAVASTATIN SODIUM 437 422 1 10
SIMVASTATIN 371 323 2 1
AMLODIPINE BESYLATE 360 360 3 2
LOSARTAN POTASSIUM 344 341 4 4
PREDNISONE 294 275 5 41
FUROSEMIDE 279 272 6 15
METFORMIN HCL 277 248 7 7
LISINOPRIL 275 248 8 3
METHOTREXATE 263 228 9 171
LEVOTHYROXINE SODIUM 247 228 10 6
METOPROLOL SUCCINATE 212 205 11 13
ATENOLOL 197 197 12 11
ALLOPURINOL 194 194 13 14
METOPROLOL TARTRATE 192 192 14 18
HYDROCHLOROTHIAZIDE 172 172 15 16
GLIPIZIDE ER 156 154 16 55
POTASSIUM CHLORIDE 153 152 17 36
HYDROXYCHLOROQUINE SULFATE 150 133 18 229
VITAMIN D2 142 142 19 134
PINDOLOL 142 142 19 237
ALENDRONATE SODIUM 141 130 21 12
ATORVASTATIN CALCIUM 141 140 21 5
HYDROCODONE-ACETAMINOPHEN 140 136 S3 23 19
DONEPEZIL HCL 137 137 24 28
DIGOXIN 133 133 25 45
ISOSORBIDE MONONITRATE ER 132 125 26 92
OMEPRAZOLE 105 93 27 9
DIOVAN 98 98 28 27
GEMFIBROZIL 91 74 29 70
GLIMEPIRIDE 89 79 30 32
BOOSTRIX 89 88 30 273
CLOPIDOGREL 88 85 32 25
KLOR-CON 10 87 87 33 183
FINASTERIDE 86 86 34 60
FOLIC ACID 81 80 35 152
TAMSULOSIN HCL 80 80 36 21
ACTONEL 79 79 37 47
FELODIPINE ER 78 78 38 23
WARFARIN SODIUM 70 66 39 20
LOVASTATIN 69 67 40 8
PLAVIX 69 68 40 40
CLONIDINE HCL 65 59 42 117
SERTRALINE HCL 63 63 43 100
PROAIR HFA 63 59 43 52
PRADAXA 60 60 45 146
PANTOPRAZOLE SODIUM 59 55 46 35
ADACEL 58 55 47 211
ACARBOSE 55 47 48 202
MECLIZINE HCL 54 54 49 81
LOSARTAN-HYDROCHLOROTHIAZIDE 54 48 49 17
COLCRYS 53 53 51 85
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 14, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.